Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 1/2010

01-03-2010 | ORIGINAL RESEARCH

Stem Cell Therapy Improves the Outcome of Liver Resection in Cirrhotics

Authors: Alaa Ismail, Ossama Fouad, Amr Abdelnasser, Andaleeb Chowdhury, Abdulhafez Selim

Published in: Journal of Gastrointestinal Cancer | Issue 1/2010

Login to get access

Abstract

Introduction

Significant proportions of liver cirrhotic patients develop hepatocellular carcinoma and have to undergo hepatic resection. The compromised cirrhotic liver cannot withstand further removal of hepatic tissue, thus, leading to postoperative complication and death.

Methods

In this study, we enrolled 20 patients having liver cirrhosis with hepatocellular carcinoma and randomly assigned them into two groups to receive autologous stem cells or placebo.

Results

After 3 weeks, all participants underwent liver resection and were followed for 12 weeks postoperative. We observed that the group receiving preoperative stem cell therapy had shown a significant improvement in all parameters of liver function and had no postoperative complications compared to the group treated with placebo, which showed no improvement in liver parameters and had postoperative complications.

Discussion

In conclusion, autologous stem cell therapy can improve the surgical outcome in cirrhotic livers and should be considered as an adjuvant treatment in such patients undergoing hepatic resection.
Literature
1.
go back to reference Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19:271–85.CrossRefPubMed Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19:271–85.CrossRefPubMed
3.
go back to reference Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology. 1997;26:1006–11.CrossRefPubMed Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology. 1997;26:1006–11.CrossRefPubMed
4.
go back to reference Jean D. (2002) Reparative medicine: growing tissues and organ. Jean D. (2002) Reparative medicine: growing tissues and organ.
5.
go back to reference Peterson BE, Bowen WC, Patrene KD, Mars WM, Sullivan AK, Murase N, et al. Bone marrow as a potential source of hepatic oval cells. Science. 1999;284:1168–70.CrossRef Peterson BE, Bowen WC, Patrene KD, Mars WM, Sullivan AK, Murase N, et al. Bone marrow as a potential source of hepatic oval cells. Science. 1999;284:1168–70.CrossRef
6.
go back to reference Thiese ND, Badve S, Saxena R, Henegariu O, Sell S, Crawford JM, et al. Derivation of hepatocytes from bone marrow cells in mice after irradiation-induced myeloablation. Hepatology. 2000;31:235–40.CrossRef Thiese ND, Badve S, Saxena R, Henegariu O, Sell S, Crawford JM, et al. Derivation of hepatocytes from bone marrow cells in mice after irradiation-induced myeloablation. Hepatology. 2000;31:235–40.CrossRef
7.
go back to reference Theise ND, Nimmakayalu M, Gardner R, Illei PB, Morgan G, Teperman L, et al. Liver from bone marrow in humans. Hepatology. 2000;32(1):11–6.CrossRefPubMed Theise ND, Nimmakayalu M, Gardner R, Illei PB, Morgan G, Teperman L, et al. Liver from bone marrow in humans. Hepatology. 2000;32(1):11–6.CrossRefPubMed
8.
go back to reference Lagasse E, Connors H, Al-Dhalimy M, Reitsma M, Dohse M, Osborne L, et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med. 2000;6:1229–34.CrossRefPubMed Lagasse E, Connors H, Al-Dhalimy M, Reitsma M, Dohse M, Osborne L, et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med. 2000;6:1229–34.CrossRefPubMed
9.
go back to reference Krause DS, Theise ND, Collector MI, Henegariu O, Hwang S, Gardner R, et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell. 2001;105:369–77.CrossRefPubMed Krause DS, Theise ND, Collector MI, Henegariu O, Hwang S, Gardner R, et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell. 2001;105:369–77.CrossRefPubMed
10.
go back to reference Esch JS 2nd, Knoefel WT, Klein M, et al. Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells. 2005;23:463–70.CrossRef Esch JS 2nd, Knoefel WT, Klein M, et al. Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells. 2005;23:463–70.CrossRef
11.
go back to reference Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y, et al. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells. 2006;24(10):2292–8.CrossRefPubMed Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y, et al. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells. 2006;24(10):2292–8.CrossRefPubMed
13.
go back to reference Weibrich G, Kleis WK, Buch R, Hitzler WE, Hafner G. The harvest smart PRePTM system versus the Friadent-Schütze platelet-rich plasma kit. Clin Oral Implants Res. 2003;14(2):233–9.CrossRefPubMed Weibrich G, Kleis WK, Buch R, Hitzler WE, Hafner G. The harvest smart PRePTM system versus the Friadent-Schütze platelet-rich plasma kit. Clin Oral Implants Res. 2003;14(2):233–9.CrossRefPubMed
14.
go back to reference Bucher NLR, Swaffield MN. The rate of incorporation of labeled thymidine into the deoxyribonucleic acid of regenerating rat liver in relation to the amount of liver excised. Cancer Res. 1964;240:1611–25. Bucher NLR, Swaffield MN. The rate of incorporation of labeled thymidine into the deoxyribonucleic acid of regenerating rat liver in relation to the amount of liver excised. Cancer Res. 1964;240:1611–25.
15.
go back to reference Stocker E, Pfeifer U. On the manner of proliferation of the liver parenchyma after partial hepatectomy. Autoradiography studies using 3H-thymidine. Naturwissenschaften. 1965;52:663.CrossRefPubMed Stocker E, Pfeifer U. On the manner of proliferation of the liver parenchyma after partial hepatectomy. Autoradiography studies using 3H-thymidine. Naturwissenschaften. 1965;52:663.CrossRefPubMed
16.
go back to reference Krbling M, Estrov Z. Adult stem cells for tissue repair—a new therapeutic concept? N Engl J Med. 2003;349:570–82.CrossRef Krbling M, Estrov Z. Adult stem cells for tissue repair—a new therapeutic concept? N Engl J Med. 2003;349:570–82.CrossRef
17.
go back to reference Dalakas E, Newsome PN, Harrison DJ, Plevris JN. Hematopoietic stem cell trafficking in liver injury. FASEB J. 2005;19(10):1225–31.CrossRefPubMed Dalakas E, Newsome PN, Harrison DJ, Plevris JN. Hematopoietic stem cell trafficking in liver injury. FASEB J. 2005;19(10):1225–31.CrossRefPubMed
18.
go back to reference Fu J, Ren Z-R. A progress of adult stem cells differentiating into liver cells. J Genet Mol Biol. 2006;17(1):29–36. Fu J, Ren Z-R. A progress of adult stem cells differentiating into liver cells. J Genet Mol Biol. 2006;17(1):29–36.
19.
go back to reference Parekkadan B, van Poll D, Suganuma K, Carter EA, Berthiaume F, Tilles AW, et al. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS ONE. 2007;2(9):e941.CrossRefPubMed Parekkadan B, van Poll D, Suganuma K, Carter EA, Berthiaume F, Tilles AW, et al. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS ONE. 2007;2(9):e941.CrossRefPubMed
20.
go back to reference Fox IJ, et al. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med. 1998;338:1422–6.CrossRefPubMed Fox IJ, et al. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med. 1998;338:1422–6.CrossRefPubMed
Metadata
Title
Stem Cell Therapy Improves the Outcome of Liver Resection in Cirrhotics
Authors
Alaa Ismail
Ossama Fouad
Amr Abdelnasser
Andaleeb Chowdhury
Abdulhafez Selim
Publication date
01-03-2010
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 1/2010
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-009-9092-9

Other articles of this Issue 1/2010

Journal of Gastrointestinal Cancer 1/2010 Go to the issue

Editorial

Editorial

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.